Patents by Inventor Anne Comi

Anne Comi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
    Publication number: 20240033229
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.
    Type: Application
    Filed: February 16, 2023
    Publication date: February 1, 2024
    Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Anne COMI
  • Compositions and methods for treating vascular malformation and related conditions
    Patent number: 11452737
    Abstract: In one aspect, the present invention features a method of inhibiting proliferation and/or reducing survival of a cell comprising a GNAQ polynucleotide or polypeptide having a R183Q or Q209L mutation, comprising contacting the cell with puromycin or a puromycin analog, thereby inhibiting proliferation and/or reducing survival of the cell. In another aspect, a method of treating a vascular malformation or related condition in a subject, comprising administering to the subject an effective amount of puromycin or a puromycin analog is featured.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: September 27, 2022
    Assignees: The Johns Hopkins University, Duke University, Kennedy Krieger Institute, Inc.
    Inventors: Anne Comi, Jonathan Pevsner, Zhenhua Huang, Doug Marchuk
  • DIAGNOSTIC AND PROGNOSTIC TEST FOR STURGE-WEBER SYNDROME, KLIPPEL-TRENAUNAY-WEBER SYNDROME, AND PORT-WINE STAINS (PWSS)
    Publication number: 20200370118
    Abstract: The present invention relates to the fields of neurological and skin disorders. More specifically, the present invention provides methods and compositions for diagnosing and prognosing Sturge-Weber Syndrome (SWS), Klippel-Trenaunay-Weber Syndrome (KTWS), and Port Wine Stains (PWS).
    Type: Application
    Filed: January 7, 2020
    Publication date: November 26, 2020
    Inventors: Jonathan Pevsner, Anne Comi, Douglas Marchuk, Matthew Shirley
  • USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
    Publication number: 20200138738
    Abstract: The present invention relates in the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Surge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.
    Type: Application
    Filed: January 8, 2020
    Publication date: May 7, 2020
    Inventors: Geoffrey GUY, Stephen WRIGHT, Alice MEAD, Anne COMI
  • Use of cannabinoids in the treatment of epilepsy
    Patent number: 10583096
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: March 10, 2020
    Assignee: GW RESEARCH LIMITED
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Anne Comi
  • Diagnostic and prognostic test for sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (PWSS)
    Patent number: 10544461
    Abstract: The present invention relates to the fields of neurological and skin disorders. More specifically, the present invention provides methods and compositions for diagnosing and prognosing Sturge-Weber Syndrome (SWS), Klippel-Trenaunay-Weber Syndrome (KTWS), and Port Wine Stains (PWS).
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: January 28, 2020
    Assignees: The Johns Hopkins University, Kennedy Krieger Institute, Inc., Duke University
    Inventors: Jonathan Pevsner, Anne Comi, Douglas Marchuk, Matthew Shirley
  • USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
    Publication number: 20190083418
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD appears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.
    Type: Application
    Filed: March 28, 2017
    Publication date: March 21, 2019
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Anne Comi
  • COMPOSITIONS AND METHODS FOR TREATING VASCULAR MALFORMATION AND RELATED CONDITIONS
    Publication number: 20180235994
    Abstract: In one aspect, the present invention features a method of inhibiting proliferation and/or reducing survival of a cell comprising a GNAQ polynucleotide or polypeptide having a R183Q or Q209L mutation, comprising contacting the cell with puromycin or a puromycin analog, thereby inhibiting proliferation and/or reducing survival of the cell. In another aspect, a method of treating a vascular malformation or related condition in a subject, comprising administering to the subject an effective amount of puromycin or a puromycin analog is featured.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 23, 2018
    Inventors: Anne Comi, Jonathan Pevsner, Zhenhua Huang, Doug Marchuk
  • DIAGNOSTIC AND PROGNOSTIC TEST FOR STURGE-WEBER SYNDROME, KLIPPEL-TRENAUNAY-WEBER SYNDROME, AND PORT-WINE STAINS (PWSS)
    Publication number: 20160237492
    Abstract: The present invention relates to the fields of neurological and skin disorders. More specifically, the present invention provides methods and compositions for diagnosing and prognosing Sturge-Weber Syndrome (SWS), Klippel-Trenaunay-Weber Syndrome (KTWS), and Port Wine Stains (PWS).
    Type: Application
    Filed: April 16, 2014
    Publication date: August 18, 2016
    Inventors: Jonathan Pevsner, Anne Comi, Douglas Marchuk, Matthew Shirley